Agios Pharmaceuticals (NASDAQ:AGIO) Stock Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $31.70 and traded as low as $29.80. Agios Pharmaceuticals shares last traded at $30.55, with a volume of 3,094,276 shares.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Agios said updated safety data showed no new cases of hepatocellular injury in sickle cell patients treated with mitapivat. The company remains confident in the drug’s benefit-risk profile, is launch-ready, and continues labeling discussions with the FDA. Agios FDA review update
• Positive Sentiment: An analyst view argued that the delay may not invalidate the bullish thesis because mitapivat demonstrated meaningful reductions in transfusion burden, despite mixed efficacy on pain-crisis endpoints. Seeking Alpha upgraded the stock, while HC Wainwright maintained a “buy” rating with a $55 price target. Agios sickle cell analysis
• Neutral Sentiment: Agios was expected to potentially beat estimates in its upcoming quarterly report, but the earnings preview provided no confirmed results or new operating data. Agios earnings preview
• Negative Sentiment: The FDA extended the PDUFA decision date for mitapivat’s sickle cell supplemental application by three months, from November 1, 2026, to February 1, 2027. The extension followed the agency’s request for additional information on whether a Risk Evaluation and Mitigation Strategy (REMS) is needed. The FDA classified Agios’ response as a major amendment, delaying a potential approval and launch timeline. Agios shares fall on FDA review extension
• Negative Sentiment: The REMS review raises concerns about possible safety-related prescribing restrictions and commercialization requirements. In addition, mitapivat did not meet the sickle-cell pain-crisis endpoint, increasing uncertainty around the breadth of its eventual label.
• Negative Sentiment: A recent pre-arranged sale by Chief Medical Officer Sarah Gheuens adds a modest negative sentiment signal, although the transaction was not identified as the primary reason for the selloff. Agios insider sale

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Citigroup lifted their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 31st. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $55.00 price target on the stock. Truist Financial decreased their price objective on shares of Agios Pharmaceuticals from $39.00 to $37.00 and set a “buy” rating on the stock in a report on Wednesday, October 7th. Royal Bank Of Canada raised their price objective on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “sector perform” rating in a research report on Tuesday, July 7th. Finally, Bank of America raised their price objective on shares of Agios Pharmaceuticals from $46.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.50.

Agios Pharmaceuticals Stock Performance

The firm’s 50-day moving average is $33.62 and its two-hundred day moving average is $31.70. The stock has a market cap of $1.82 billion, a P/E ratio of -4.36 and a beta of 0.63.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.04). The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -5.81 EPS for the current year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 7,866 shares of the business’s stock in a transaction on Monday, October 26th. The stock was sold at an average price of $37.69, for a total transaction of $296,469.54. Following the completion of the sale, the insider owned 54,645 shares in the company, valued at $2,059,570.05. The trade was a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 39,855 shares of company stock worth $1,285,512 in the last ninety days. Insiders own 5.40% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in Agios Pharmaceuticals during the 3rd quarter worth about $101,000. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in shares of Agios Pharmaceuticals by 4.0% in the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 28,861 shares of the biopharmaceutical company’s stock valued at $960,000 after purchasing an additional 1,100 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Agios Pharmaceuticals by 15.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,893 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 1,428 shares during the last quarter. Inspire Investing LLC boosted its stake in shares of Agios Pharmaceuticals by 4.7% in the 3rd quarter. Inspire Investing LLC now owns 19,130 shares of the biopharmaceutical company’s stock valued at $636,000 after purchasing an additional 861 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in shares of Agios Pharmaceuticals by 1,714.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock worth $62,723,000 after buying an additional 1,782,457 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.